Xiaohui Li1, Zetian Jia2, Yaqi Yan3. 1. School of Life Science and Enginering, Handan University, Handan, People's Republic of China. 2. Department of Neurosurgery, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, People's Republic of China. 3. Department of Cardiology, The First Hospital of Handan of Hebei Province, Handan, 056000, People's Republic of China. 514665435@qq.com.
Abstract
BACKGROUND: Tumor-treating fields (TTF) is a novel cancer treatment that uses alternating electric fields to interfere with tumor cell mitosis. It has been approved by the U.S. food and drug administration for the treatment of recurrent glioblastoma (rGBM). We designed this meta-analysis to evaluate the efficacy and safety of TTF in the treatment of rGBM. METHODS: The study was based on the PRISMA guideline. Systematic retrieval was performed in PubMed, Cochrane Library, and Embase databases. The outcomes were overall survival (OS) hazard ratio (HR), 1-year survival rate, and cutaneous toxicity. RESULTS: These studies included a total of 1048 rGBM patients who received TTF treatment. The overall survival time between the TTF group and the control group was HR 0.75 ([95%CI 0.63 to 0.89]; P = 0.001). Pooled 1-year overall survival rate and incidence of cutaneous toxicity were 0.47 and 0.48, respectively. Data were insufficient to evaluate the effect of MGMT methylation status and tumor recurrence times on heterogeneity. CONCLUSIONS: TTF therapy is effective for recurrent glioblastoma. However, most relevant trials should assess rGBM patient baseline characteristics such as age, KPS, MGMT methylation status, and number of tumor recurrence,. In addition, the risk of rashes caused by long-term wearing of devices should also be considered.
BACKGROUND: Tumor-treating fields (TTF) is a novel cancer treatment that uses alternating electric fields to interfere with tumor cell mitosis. It has been approved by the U.S. food and drug administration for the treatment of recurrent glioblastoma (rGBM). We designed this meta-analysis to evaluate the efficacy and safety of TTF in the treatment of rGBM. METHODS: The study was based on the PRISMA guideline. Systematic retrieval was performed in PubMed, Cochrane Library, and Embase databases. The outcomes were overall survival (OS) hazard ratio (HR), 1-year survival rate, and cutaneous toxicity. RESULTS: These studies included a total of 1048 rGBM patients who received TTF treatment. The overall survival time between the TTF group and the control group was HR 0.75 ([95%CI 0.63 to 0.89]; P = 0.001). Pooled 1-year overall survival rate and incidence of cutaneous toxicity were 0.47 and 0.48, respectively. Data were insufficient to evaluate the effect of MGMT methylation status and tumor recurrence times on heterogeneity. CONCLUSIONS: TTF therapy is effective for recurrent glioblastoma. However, most relevant trials should assess rGBM patient baseline characteristics such as age, KPS, MGMT methylation status, and number of tumor recurrence,. In addition, the risk of rashes caused by long-term wearing of devices should also be considered.
Authors: Mario E Lacouture; Mary Elizabeth Davis; Grace Elzinga; Nicholas Butowski; David Tran; John L Villano; Lucianna DiMeglio; Angela M Davies; Eric T Wong Journal: Semin Oncol Date: 2014-03-19 Impact factor: 4.929
Authors: Eilon D Kirson; Vladimír Dbalý; Frantisek Tovarys; Josef Vymazal; Jean F Soustiel; Aviran Itzhaki; Daniel Mordechovich; Shirley Steinberg-Shapira; Zoya Gurvich; Rosa Schneiderman; Yoram Wasserman; Marc Salzberg; Bernhard Ryffel; Dorit Goldsher; Erez Dekel; Yoram Palti Journal: Proc Natl Acad Sci U S A Date: 2007-06-05 Impact factor: 11.205
Authors: Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne Journal: BMJ Date: 2011-10-18
Authors: Almuth F Kessler; Greta E Frömbling; Franziska Gross; Mirja Hahn; Wilfrid Dzokou; Ralf-Ingo Ernestus; Mario Löhr; Carsten Hagemann Journal: Cell Death Discov Date: 2018-07-16
Authors: Mario E Lacouture; Milan J Anadkat; Matthew T Ballo; Fabio Iwamoto; Suriya A Jeyapalan; Renato V La Rocca; Margaret Schwartz; Jennifer N Serventi; Martin Glas Journal: Front Oncol Date: 2020-07-28 Impact factor: 6.244